The pipeline in headache therapy

Sarah Vollbracht, Alan M. Rapoport

Research output: Contribution to journalReview article

14 Scopus citations

Abstract

Migraine is a common, disabling, neurovascular disorder characterized by episodic attacks of head pain and associated disability plus systemic autonomic and neurologic symptoms. The advent of the triptan class of medication in the 1990s revolutionized the acute treatment of migraine, but many migraineurs do not respond optimally or at all to triptans, have intolerable adverse effects, or have contraindications to their use. Preventive pharmacotherapy has advanced mostly through serendipity, with new drugs being found effective while being used for other indications. There remains a significant need for new medications and devices that can provide effective, rapid, and sustained pain relief without adverse effects or recurrence. Several new acute and preventive therapies for the treatment of migraine and cluster headaches have shown promise and are currently under investigation. This article covers innovative delivery mechanisms, calcitonin gene-related peptide receptor antagonists, antibodies to calcitonin gene-related peptide and its receptor, 5-HT1F receptor agonists, transient receptor potential vanilloid receptor modulators, orexin receptor antagonists, glial cell modulators, and neurostimulation.

Original languageEnglish (US)
Pages (from-to)717-729
Number of pages13
JournalCNS Drugs
Volume27
Issue number9
DOIs
StatePublished - Sep 1 2013

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'The pipeline in headache therapy'. Together they form a unique fingerprint.

  • Cite this

    Vollbracht, S., & Rapoport, A. M. (2013). The pipeline in headache therapy. CNS Drugs, 27(9), 717-729. https://doi.org/10.1007/s40263-013-0090-x